Identity
- Trade Name
- Thermo Scientific Pacific Hemostasis® FDA UDI
- Generic Name
- Plasma protein IVD, reagent FDA UDI
- Model / Reference
- 100050 FDA UDI
Identifiers
- Primary DI / UDI-DI
- 00845275000696 FDA UDI
- FDA Product Code
- GJT FDA UDI
- GMDN Term
- Plasma protein IVD, reagent FDA UDI
Classification
- Device Class
- Class II FDA UDI
- Regulation Number
- 864.7290 FDA UDI
- Commercial Distribution
- In Commercial Distribution FDA UDI
Clinical & Handling
Sterile
No
FDA UDI
Single Use
Yes
FDA UDI
Implantable
No
FDA UDI
Contains Latex
No
FDA UDI
Prescription Use
No
FDA UDI
Over-the-Counter
No
FDA UDI
Convenience Kit
No
FDA UDI
Combination Product
No
FDA UDI
HCT/P
No
FDA UDI
Premarket Exempt
Yes
FDA UDI
Lot / Batch Number
Yes
FDA UDI
Serial Number
No
FDA UDI
Expiration Date
Yes
FDA UDI
Manufacturing Date
No
FDA UDI
Category: Plasma protein IVD, reagent
Thermo Scientific Pacific Hemostasis® by Fisher Diagnostics — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS
Similar devices
Also classified as Plasma protein IVD, reagent.
- ImmunoCAP Specific IgA/IgG Sample Diluent — Phadia GmbH · Class II
- ImmunoCAP IgE/ECP/Tryptase Sample Diluent — Phadia GmbH · Class II
- Maintenance Solution Kit Large — Phadia GmbH · Class I
- EliA Sample Diluent — Phadia GmbH · Class II
- Maintenance Solution Kit — Phadia GmbH · Class I
- ImmunoCAP Autoimmunity Specific IgG Sample Diluent — Phadia GmbH · Class I
- Development Solution — Phadia GmbH · Class II
- ImmunoCAP Autoimmunity Specific IgG Sample Diluent — Phadia GmbH · Class I
Authorization Coverage (1 country)
Regulatory Authorizations
United States Pending data
FDA UDI
| Source | Region | Type | Cert / Approval No. | Class | Status |
|---|---|---|---|---|---|
| FDA UDI | United States | FDA UDI | Registered in GUDID | Class II | Pending data |
Is this your device? Claim it to add documentation and request validation.
Manufacturer
- Manufacturer
- Fisher Diagnostics
Sources (1)
- FDA UDI aef0acf8-55fe-45cd-a26d-e8abd9fda5fe 34 fields · synced Jun 8, 2026